Cellectis S.A. (NASDAQ:CLLS) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analysts rate Cellectis “Moderate Buy”: Four analysts recommend buying, one recommends a strong buy, and one rates the stock a sell. The average 12-month price target is $7.00, with Barclays and Citizens JMP setting targets of $9.00 and $8.00, respectively.
• CLLS shares opened at $2.76, down 2.8%, with a 52-week range of $2.35 to $5.48. In its latest quarter, Cellectis reported an adjusted loss of $0.22 per share—better than expected—but revenue of $6.9 million fell short of the $11.05 million estimate.
• Institutional investors own 63.9% of Cellectis, with several firms recently initiating or increasing positions. The clinical-stage biotechnology company develops gene-edited CAR-T cell therapies for cancer using its TALEN platform.

Shares of Cellectis S.A. (NASDAQ:CLLS - Get Free Report) have been given an average rating of "Moderate Buy" by the six brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $7.00.

Several research analysts recently issued reports on CLLS shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cellectis in a research report on Friday, July 17th. Barclays assumed coverage on shares of Cellectis in a research report on Thursday, May 28th. They issued an "overweight" rating and a $9.00 price objective for the company. Finally, Citizens Jmp reiterated a "market outperform" rating and set a $8.00 target price on shares of Cellectis in a research report on Tuesday, April 14th.

Cellectis Trading Down 2.8%

Shares of CLLS opened at $2.76 on Tuesday. The stock has a fifty day moving average price of $2.94 and a two-hundred day moving average price of $3.46. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.37 and a current ratio of 1.37. Cellectis has a 52-week low of $2.35 and a 52-week high of $5.48. The company has a market cap of $276.94 million, a price-to-earnings ratio of -4.25 and a beta of 2.91.

Cellectis (NASDAQ:CLLS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.04. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.The company had revenue of $6.90 million for the quarter, compared to analyst estimates of $11.05 million.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Global Retirement Partners LLC bought a new stake in Cellectis in the fourth quarter valued at about $34,000. Lido Advisors LLC bought a new position in Cellectis during the first quarter worth about $32,000. Millennium Management LLC boosted its holdings in Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company's stock worth $165,000 after buying an additional 22,080 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Cellectis during the 3rd quarter worth about $72,000. Finally, Acadian Asset Management LLC grew its position in shares of Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after buying an additional 26,461 shares during the period. Institutional investors and hedge funds own 63.90% of the company's stock.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company's core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source